SHSE:688266 (China)
Â
Class A
Â¥
112.22
+1.87 (+1.69%)
Aug 6
Business Description
Suzhou Zelgen Biopharmaceuticals Co Ltd
ISIN : CNE100003RP1
Share Class Description:
SHSE:688266: Class ATotal Employee Number:
1,055Compare
Compare
Traded in other countries / regions
688266.China Index Membership
SSE Composite IndexCSI 500 Index IPO Date
2020-01-23Description
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.04 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | 1.43 | |||||
Interest Coverage | 24.55 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 10.39 | |||||
Beneish M-Score | -2.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 34.7 | |||||
3-Year EBITDA Growth Rate | 40.6 | |||||
3-Year EPS without NRI Growth Rate | 28.6 | |||||
3-Year FCF Growth Rate | 25.3 | |||||
3-Year Book Growth Rate | 8.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 43.61 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.49 | |||||
9-Day RSI | 34.99 | |||||
14-Day RSI | 40.64 | |||||
3-1 Month Momentum % | 37.5 | |||||
6-1 Month Momentum % | 58.01 | |||||
12-1 Month Momentum % | 26.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.5 | |||||
Quick Ratio | 2.34 | |||||
Cash Ratio | 2.08 | |||||
Days Inventory | 623.37 | |||||
Days Sales Outstanding | 39.79 | |||||
Days Payable | 862.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 0.04 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.7 | |||||
Operating Margin % | 32.38 | |||||
Net Margin % | 33.52 | |||||
EBITDA Margin % | 34.69 | |||||
FCF Margin % | 39.36 | |||||
OCF Margin % | 48.58 | |||||
ROE % | 40.2 | |||||
ROA % | 16.98 | |||||
ROIC % | 36.31 | |||||
3-Year ROIIC % | 42.24 | |||||
ROC (Joel Greenblatt) % | 115.33 | |||||
ROCE % | 29.8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 53.95 | |||||
Forward PE Ratio | 62.23 | |||||
PE Ratio without NRI | 53.8 | |||||
Price-to-Owner-Earnings | 62.4 | |||||
PEG Ratio | 1.84 | |||||
PS Ratio | 18.11 | |||||
PB Ratio | 17.26 | |||||
Price-to-Tangible-Book | 17.51 | |||||
Price-to-Free-Cash-Flow | 46.05 | |||||
Price-to-Operating-Cash-Flow | 37.31 | |||||
EV-to-EBIT | 49.35 | |||||
EV-to-EBITDA | 49.35 | |||||
EV-to-Revenue | 17.12 | |||||
EV-to-FCF | 43.5 | |||||
Price-to-GF-Value | 0.51 | |||||
Price-to-Graham-Number | 6.47 | |||||
| Price-to-Net-Current-Asset-Value | 25.68 | |||||
| Price-to-Net-Cash | 44.71 | |||||
Earnings Yield (Greenblatt) % | 2.03 | |||||
FCF Yield % | 2.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Suzhou Zelgen Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,640.214 | ||
| EPS (TTM) (Â¥) | 2.08 | ||
| Beta | 0.6538 | ||
| 3-Year Sharpe Ratio | 0.87 | ||
| 3-Year Sortino Ratio | 1.56 | ||
| Volatility % | 38.37 | ||
| 14-Day RSI | 40.64 | ||
| 14-Day ATR (Â¥) | 10.653368 | ||
| 20-Day SMA (Â¥) | 132.0975 | ||
| 12-1 Month Momentum % | 26.94 | ||
| 52-Week Range (Â¥) | 75.1 - 160 | ||
| Shares Outstanding (Mil) | 264.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Suzhou Zelgen Biopharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Suzhou Zelgen Biopharmaceuticals Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Suzhou Zelgen Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266)'s stock price today?
The current price of SHSE:688266 is ¥112.22. The 52 week high of SHSE:688266 is ¥160.00 and 52 week low is ¥75.10.
When is next earnings date of Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266)?
The next earnings date of Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266) is .
Does Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266) pay dividends? If so, how much?
Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Suzhou Zelgen Biopharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers